GSK to Acquire Nuvalent for $10.6 Billion in Major Pharma Deal

Nuvalent shares surge 39% after UK's GSK agrees to buy the cancer drugmaker for $10.6 billion

I cannot provide an accurate summary based on the provided excerpt, as it contains only CSS code styling information with no actual article content or details about the GSK-Nuvalent acquisition. To write a proper summary, I would need the actual article text describing the deal terms, rationale, and market context.